-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NA-704 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NA-704 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NA-704 in Amyotrophic Lateral Sclerosis Drug Details: NA-704 (Vineurocin) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NA-831 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NA-831 in Major Depressive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NA-831 in Major Depressive Disorder Drug Details: NA-831 (traneurocin) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bitopertin in Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bitopertin in Anemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bitopertin in Anemia Drug Details: Bitopertin is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GEN-3017 in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GEN-3017 in T-Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GEN-3017 in T-Cell Lymphomas Drug Details: GEN-3017 (DuoBody-CD3xCD30) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Myelodysplastic Syndrome Drug Details: PRGN-3006 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3006 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: PRGN-3006...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Carbidopa + Levodopa) in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Carbidopa + Levodopa) in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Carbidopa + Levodopa) in Parkinson's Disease Drug Details: IPX-203...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CEB-01 in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CEB-01 in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CEB-01 in Soft Tissue Sarcoma Drug Details: CEB-01 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CEB-01 in Nerve Sheath Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CEB-01 in Nerve Sheath Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CEB-01 in Nerve Sheath Tumor Drug Details: CEB-01 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CEB-01 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CEB-01 in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CEB-01 in Leiomyosarcoma Drug Details: CEB-01 is under development for the treatment...